CN101797340B - Composite drug for curing esophageal carcinoma and preparation method thereof - Google Patents
Composite drug for curing esophageal carcinoma and preparation method thereof Download PDFInfo
- Publication number
- CN101797340B CN101797340B CN2010101337387A CN201010133738A CN101797340B CN 101797340 B CN101797340 B CN 101797340B CN 2010101337387 A CN2010101337387 A CN 2010101337387A CN 201010133738 A CN201010133738 A CN 201010133738A CN 101797340 B CN101797340 B CN 101797340B
- Authority
- CN
- China
- Prior art keywords
- parts
- esophageal carcinoma
- preparation
- medicine
- cera flava
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a drug for curing esophageal carcinoma and discloses a composite drug for curing esophageal carcinoma and a preparation method thereof. The composite drug contains the medical ingredients of 20 parts of placenta hominis, 4 parts of centipede, 4 parts of senso, 10 parts of membrane of chicken gizzard, 20 parts of crude arrowhead, 20 parts of processed rhizoma pinelliae, 15parts of saffron, 20 parts of anhydrous sodium sulphate and 50 parts of beewax by weight. The preparation method includes the steps of chopping the medical ingredients except the beewax, putting the chopped ingredients in a porcelain jar for dry-frying, then mixing, grinding and sieving, and collecting the powder mixture; thawing the beewax in a copper dipper, then adding the powder mixture to prepare the mixture to be a preparation, and finally heating, humidifying and granulating.
Description
Technical field
The present invention relates to be used for the treatment of the medicine of the esophageal carcinoma, particularly a kind of composition of medicine that is used for the treatment of the esophageal carcinoma and preparation method thereof.
Background technology
The esophageal carcinoma is a kind of common cancer, and annual nearly 200,000 people in the whole world die from the esophageal carcinoma.The incidence rate of the esophageal carcinoma and mortality rate occupy the 4th in China's malignant tumor, very harmful to people ' s health.The treatment of the esophageal carcinoma is based on operation and chemicotherapy, but owing to early diagnosis is difficult for, the patient of 70%-80% has entered clinical middle and advanced stage during prescription on individual diagnosis, total 5 year life cycle about 28% behind operation and the chemicotherapy.Operation is big to patient's strike, complication is high; And chemicotherapy has a lot of toxic and side effects, and in kill cancer cell, a large amount of normal cells that kill make patient's immune system be subjected to heavy damage, causes cancer metastasis, recurs, is difficult to control.Up to now, be not diffused into the patient with esophageal carcinoma at other positions, do not find still that a kind of curative effect height, cost are low, no pain, toxic and side effects Therapeutic Method and medicine little, easy to use for esophageal cancer cell.
Summary of the invention
A kind of curative effect height of purpose of the present invention, cost are low, no pain, toxic and side effects are little, easy to use is used for the treatment of composition of medicine of the esophageal carcinoma and preparation method thereof.
In order to achieve the above object, the present invention is achieved by the following technical solutions.
(1) a kind of composition of medicine that is used for the treatment of the esophageal carcinoma is characterized in that, is made up of following medicaments in part by weight component: 20 parts of Placenta Hominiss, 4 parts of Scolopendras, 4 parts of Venenum Bufoniss, 10 parts of Endothelium Corneum Gigeriae Galli, 20 parts of Pseudobulbus Cremastrae seu Pleiones, 20 parts of Rhizoma Pinelliae Preparata, 15 parts of Stigma Crocis, 20 parts of Matrii Sulfas Exsiccatus, 50 parts in Cera Flava.
(2) a kind of preparation method that is used for the treatment of the composition of medicine of the esophageal carcinoma, it is characterized in that, may further comprise the steps: at first take by weighing each drug component according to the described weight portion of technical scheme (1), after other each drug components beyond the Cera Flava are shredded respectively, placing Porcelain Jar to do fries, mix subsequently, grind, sieve, collect mixed-powder; Melt Cera Flava then in the copper wooden dipper, add mixed-powder preparation molding, the humidifying of heating is at last made granule.
In the composition of medicine of the present invention, Placenta Hominis has the conditioning function of eliminating pathogenic factor for supporting vital QI, benefiting qi and nourishing blood, nourishing the liver and kidney; Scolopendra has the function of dispersing pathogen accumulation, alleviating pain and detumescence, collateral dredging tumor; Venenum Bufonis has the function of understand things pain-stopping, town's carbuncle diuresis, removing toxic substances and promoting subsidence of swelling, dispersion cancerous cell; Endothelium Corneum Gigeriae Galli has the activating the spleen that helps digestion, changes the function that heavily fortified point helps digestion, heat extraction is only tired; Pseudobulbus Cremastrae seu Pleiones has heat-clearing and toxic substances removing, hard masses softening and resolving, town's carbuncle antidotal function; Rhizoma Pinelliae Preparata has relieving cough and resolving phlegm, the flatulence uncomfortable in chest that disappears, the town nausea and vomiting function; Stigma Croci has the function of the decomplexing that stimulates the menstrual flow, stasis-dispelling and pain-killing, blood circulation promoting and blood stasis dispelling; Matrii Sulfas Exsiccatus has the function of clearing away heat-fire, moistening for dryness and softening hard mass, detoxifcation relieving constipation; Cera Flava is warm in nature nontoxic, the counteracting toxic substances that can detoxify, and synthetic good medicine makes up a prescription.
Behind the drug oral that the present invention makes, can depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, hard masses softening and resolving, reduce phlegm, detumescence, heat-clearing and toxic substances removing, the sharp diaphragm of the chest stuffiness relieving, educate that sun promotes the production of body fluid, tonifying speen and tonifying kidney, drawing pus out and diminishing inflammation, anti-ly just consolidate, wind-expelling pain-stopping, the esophageal carcinoma had curative effect preferably.
The specific embodiment
The pharmacy example:
At first take by weighing 20 parts of Placenta Hominiss, 4 parts of Scolopendras, 4 parts of Venenum Bufoniss, 10 parts of Endothelium Corneum Gigeriae Galli, 20 parts of Pseudobulbus Cremastrae seu Pleiones, 20 parts of Rhizoma Pinelliae Preparata, 15 parts of Stigma Crocis, 20 parts of Matrii Sulfas Exsiccatus, 50 parts in Cera Flava, every part 10 gram.After other each drug components beyond the Cera Flava are shredded respectively, place Porcelain Jar to do and fry, mix subsequently, grind, sieve, collect mixed-powder; Melt Cera Flava then in the copper wooden dipper, add mixed-powder preparation molding, the humidifying of heating is at last made granule, every about 1.8 grams.
Composition of medicine function of the present invention with cure mainly: depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, hard masses softening and resolving, reduce phlegm, the sharp diaphragm of detumescence, heat-clearing and toxic substances removing, the chest stuffiness relieving, educate that sun promotes the production of body fluid, tonifying speen and tonifying kidney, drawing pus out and diminishing inflammation, anti-ly just consolidate, wind-expelling pain-stopping, the esophageal carcinoma had curative effect preferably.
Usage and consumption: three times on the one, each 1.8 grams, boiled water is taken after mixing it with water.
Note taboo: be not taken by pregnant women, children's reduces by half, and avoids the food of eating fibre rich such as Folium Allii tuberosi.
Storage: put the sealing of shady and cool place and preserve.
Clinical example:
Case is selected: 100 routine patient with esophageal carcinoma, wherein male 61 examples, women 39 examples, age reckling 37 years old, the maximum 74 years old.
Therapeutic Method: take composition of medicine of the present invention, three times on the one, each 1.8 grams, boiled water is taken after mixing it with water.Per 40 days courses of treatment.Drug withdrawal is had a rest a week after taking 2 courses of treatment continuously, observes change of illness state inspection in detail, carries out the 3rd course of therapy then, withdraws other medicines at period in a medicine.
Criterion of therapeutical effect:
Clinical cure: the positive sign of symptom and objective determination disappears, and recovers certain work capacity, observes 1 year no recidivist continuously.
Clinical produce effects: symptom disappears substantially, and focus is dwindled more than 1 half, and other objective determinations are clearly better, and observes continuously and does not have development person half a year.
Clinical effective: symptom makes moderate progress, and focus is basicly stable, observes no development person more than January.
Clinical invalid: symptom and objective determination do not have improvement, or only have short-term to improve, and deterioration person rapidly.
Experimental result: clinical cure rate 52%, clinical obvious effective rate 77%, clinical effective rate 93%; Clinical inefficiency only has 7%.
Claims (2)
1. a composition of medicine that is used for the treatment of the esophageal carcinoma is characterized in that, is made up of following medicaments in part by weight component: 20 parts of Placenta Hominiss, 4 parts of Scolopendras, 4 parts of Venenum Bufoniss, 10 parts of Endothelium Corneum Gigeriae Galli, 20 parts of Pseudobulbus Cremastrae seu Pleiones, 20 parts of Rhizoma Pinelliae Preparata, 15 parts of Stigma Crocis, 20 parts of Matrii Sulfas Exsiccatus, 50 parts in Cera Flava.
2. preparation method that is used for the treatment of the composition of medicine of the esophageal carcinoma, it is characterized in that, may further comprise the steps: at first take by weighing each drug component according to the described weight portion of claim 1, after other each drug components beyond the Cera Flava are shredded respectively, placing Porcelain Jar to do fries, mix subsequently, grind, sieve, collect mixed-powder; Melt Cera Flava then in the copper wooden dipper, add mixed-powder preparation molding, the humidifying of heating is at last made granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101337387A CN101797340B (en) | 2010-03-26 | 2010-03-26 | Composite drug for curing esophageal carcinoma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101337387A CN101797340B (en) | 2010-03-26 | 2010-03-26 | Composite drug for curing esophageal carcinoma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101797340A CN101797340A (en) | 2010-08-11 |
| CN101797340B true CN101797340B (en) | 2011-09-28 |
Family
ID=42593281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101337387A Expired - Fee Related CN101797340B (en) | 2010-03-26 | 2010-03-26 | Composite drug for curing esophageal carcinoma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101797340B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102430055A (en) * | 2011-12-08 | 2012-05-02 | 中国人民解放军第四军医大学 | Combined medicine for treating digestive tract cancer and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326772A (en) * | 2001-06-15 | 2001-12-19 | 陈延清 | Medicine for curing carcinoma of esophagus and its preparing method |
| CN1410095A (en) * | 2002-11-21 | 2003-04-16 | 杜仰恩 | Chinese patent medicine for treating esophagus cancer |
| CN101249235A (en) * | 2008-03-29 | 2008-08-27 | 李玉林 | Chinese medicine for curing esophagus cancer and method of preparing the same |
-
2010
- 2010-03-26 CN CN2010101337387A patent/CN101797340B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326772A (en) * | 2001-06-15 | 2001-12-19 | 陈延清 | Medicine for curing carcinoma of esophagus and its preparing method |
| CN1410095A (en) * | 2002-11-21 | 2003-04-16 | 杜仰恩 | Chinese patent medicine for treating esophagus cancer |
| CN101249235A (en) * | 2008-03-29 | 2008-08-27 | 李玉林 | Chinese medicine for curing esophagus cancer and method of preparing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101797340A (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463500B (en) | Medicament for treating cerebral hemorrhage | |
| CN102920959A (en) | Capsule for removing pathogenic heat from blood | |
| CN103041341B (en) | Traditional Chinese medicine composition for curing tuberculous exadative pleurisy and preparation method thereof | |
| CN104547778B (en) | A kind of for the radiation-resistant Chinese medicine preparation of Ultrasonography and preparation method | |
| CN102114172A (en) | Traditional Chinese medicine for treating hyperplasia of prostate | |
| CN101797340B (en) | Composite drug for curing esophageal carcinoma and preparation method thereof | |
| CN101406633B (en) | Pellet for recuperation of neck and waist | |
| CN102327350A (en) | Traditional Chinese medicine for treating prostatic hyperplasia | |
| CN103238711A (en) | Food healthcare tea granules for promoting lead excreting | |
| CN102389522A (en) | Traditional Chinese medicine for treating prostatic hyperplasia | |
| CN102327388A (en) | Traditional Chinese medicine for treating diabetic nephropathy | |
| CN110787253A (en) | Formula and preparation method of traditional Chinese medicine hot compress medicine bag for relieving dysmenorrhea | |
| CN1114885A (en) | External-use medicine powder for health care, nourishing kidney and clearing brain | |
| CN103566245B (en) | A kind of medicine for the treatment of nephropathy | |
| CN103960668B (en) | A kind of cynomorium songaricum saline cistanche composition and method of making the same | |
| CN102430055A (en) | Combined medicine for treating digestive tract cancer and preparation method thereof | |
| CN102397465B (en) | Traditional Chinese medicine for treating nanism, activating self growth potential, invigorating brain and increasing intelligence | |
| CN103223107A (en) | Traditional Chinese medicine used for adjusting blood fat and blood pressure, and preparation technology thereof | |
| CN101933743A (en) | Traditional Chinese medical health pillow | |
| CN102380023A (en) | Chinese medicament for treating benign prostatic hyperplasia | |
| CN102389477A (en) | Traditional Chinese medicine for treating benign prostatic hyperplasia | |
| CN102091271A (en) | Medicine for treating hyperplasia of mammary glands and preparation method thereof | |
| CN102526470B (en) | Medicinal composition for treating primary hypertension | |
| CN101843718B (en) | Chinese medicament for treating lupus erythematosus | |
| CN1853694B (en) | Medicinal composition for treating leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110928 Termination date: 20130326 |